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Abstract 
 
Metastasis is the main cause of death in cancer patients and understanding mechanisms that control 
tumor cell dissemination may lead to improved therapy. Tumor cell adhesion receptors contribute to 
cancer spreading. We noted earlier that tumor cells expressing the adhesion receptor integrin v3 can 
carry the molecule in distinct states of activation, and that cells that metastasize from the blood stream 
express it in a constitutively high affinity form. Here, we analyzed steps of the metastatic cascade in vivo 
and asked when and how the affinity state of integrin v3 confers a critical advantage to disseminating 
cancer cells. Following tumor cells by real time PCR, non-invasive bioluminescence imaging, intravital 
microscopy and histology in chick embryos and SCID mice, we identified tumor cell extravasation from 
the blood stream as a rate-limiting step that is supported by high affinity v3. We found in vitro and in 
vivo that successful transendothelial migration depended on cooperation between the tumor cells and 
platelets involving the high affinity tumor cell integrin and release of platelet granules. Thus, this study 
identifies activated tumor cell integrin v3 as critical for early steps of metastasis from the blood 
stream and highlights the high affinity conformation of the receptor and interaction with platelets as 
potential targets for prevention of metastatic disease. 
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Introduction    
 
As cancer progresses, tumor cells disseminate from primary tumors to distant sites via the lymphatics or 
blood stream. Circulating tumor cells attach to the microvasculature of target organs, penetrate the 
vessel wall, and survive and proliferate within their new tissue microenvironments. Each step can be rate 
limiting and involve adhesion receptors such as integrins (1). Integrins are heterodimeric transmembrane 
receptors that recognize extracellular matrix proteins and may exist in high or low affinity states. The 
affinity can determine ligand recognition and signals that impact cell survival, adhesion, migration, and 
invasion (2-7). Integrin affinity is regulated inside the cell and controls the adhesive phenotype and 
ability to bind soluble ligand (8). Integrin activation to high affinity is especially important for 
leukocytes and platelets, which circulate within the blood stream and can abruptly change their adhesive 
properties upon stimulation to interact with the vessel wall at sites of vascular injury or inflammation (9-
11). Integrin activation can further control cell mobilization from bone marrow and other tissues to enter 
the circulation and relocate to distant tissue niches (12).  
We previously showed that human tumor cells can express the adhesion receptor integrin v3 in 
distinct states of activation and that tumor cells carrying the high affinity form of the receptor 
metastasize most efficiently (13). Here, we asked which steps of the metastatic cascade are influenced 
by integrin activation in tumor cells, and which mechanisms are involved in integrin activation-
dependent metastasis. We showed earlier by blood perfusion in vitro that expression of v3 in a high 
affinity state enables tumor cells to interact with platelets and arrest at components of the vessel wall 
despite shear forces of blood flow (13, 14). Furthermore, we found that activated v3 helps activate 
metalloproteinase MMP-9 and supports invasive tumor cell migration (15). In the present study, we 
followed steps of the metastatic cascade in vivo and examined if, when, and how expression of activated 
v3 confers a critical advantage to disseminating tumor cells. We used chick embryos and immune 
deficient mice to follow tumor cells by real time PCR, non-invasive bioluminescence imaging, intravital 
microscopy, and histology and analyzed the impact of v3-activation on primary tumor growth, 
intravasation, tumor cell dissemination, and target organ colonization.  The results indicate that 
expression of high affinity tumor cell v3 is not required for primary tumor growth, but does promote 
initial steps of target organ colonization from the blood stream to multiple metastatic sites. The 
mechanism by which activated v3 supports tumor cell access to target tissues depends on platelets 
which assist tumor cell extravasation.  
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Materials and Methods 
 
Cell lines, labeling, and in vivo model 
MDA-MB 435 human tumor cells were from Dr. Janet Price (MD Anderson). Variants of the parental 
cells lacking v3 and reconstituted with v3WT or v3D723R were previously described (13). 
Clone E9 cells were isolated by limiting dilution of the parental cells. Parent Combo cells represent a 
pool of 20 clones, each expressing non-activated v3 based on in vitro migration and blood perfusion 
as detailed below.  
 
For in vivo tracking, the tumor cells were stably transduced with red fluorescent protein (dsRed2) or 
firefly luciferase (Fluc) using a self-inactivating lentiviral vector (16). For hematogenous metastasis, 
1x105 - 1x106 tumor cells were injected into the tail vein of 5- to 8-week old female C.B17/lcTac-Prkdc 
scid mice (Taconic) and metastatic activity followed by non-invasive bioluminescence imaging 
(IVIS200) (17), fluorescence microscopy of lung whole mounts, or real time PCR of human alu 
sequences in lung extracts using sense primer 5’ ACG CCT GTA ATC CCA GCA CTT 3’ and antisense 
primer 5’ TCG CCC AGG CTG GAG TGC A 3’ (18).  
 
Induction of thrombocytopenia  
Thrombocytopenia was induced by i.v. injecting SCID mice with anti-murine GPIbα (CD42b) (Emfret) 
(3 μg/g bodyweight).  
 
Flow cytometry 
Integrin expression and v3 activation were analyzed by flow cytometry (FACS Calibur, Becton 
Dickinson) with anti v3 mAb VNR1-27.1 (19), or activation-dependent human ligand-mimetic scFv 
antibodies Bc-12 and Bc-15 (20). ScFv binding was detected with M2 mouse anti-FLAG and anti-
mouse-APC using TBS with or without 1mM EDTA, 1mM Ca2+, or 0.1 mM Mn2+ as binding and 
washing buffer.  
 
In vitro migration and arrest during blood flow 
Haptotactic migration toward human extracellular matrix proteins was detailed earlier (21). 
Cancer cell arrest during blood flow was measured as described (13). Briefly, dsRed tagged tumor cells 
(red fluorescence) were suspended in human blood anticoagulated with 50 nM -Pro-Arg-chloro methyl 
ketone,  spiked with 10 M mepacrine (green fluorescence) and perfused over collagen I or 
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subendothelial matrix at a venous wall shear rate of 50 s-1 (4 dynes/cm2). Adhesive events and cell 
interactions were recorded by fluorescence video microscopy and quantified at 50 predefined positions 
by image analysis using MetaMorph software.  
 
Dorsal skin fold chamber and intravital microscopy 
Tumor cell interaction with the pulmonary microvasculature was observed by intravital microscopy in 
lung allografts grown in dorsal skin fold chambers on SCID mice as described (22). Briefly, titanium 
frames were implanted into a dorsal skin fold, transplanted with SCID lung allografts 3 days later, and 
allowed to vascularize for 14 days. The allografts were superfused with TNF (50l at 1g/ml) 2.5 
hours before injecting 2.5x106 dsRed tagged tumor cells i.v. together with FITC-dextran (500 kDa) to 
visualize the vasculature. Adhesive events were observed with an intravital microscope (Leitz Biomed) 
(22). 
 
Transendothelial migration and platelet preparation 
Human pulmonary microvascular endothelial cells were grown for 5 days on transwell filters (8 m 
pores) coated with human fibronectin (10μg/ml). Monolayer integrity was measured by transendothelial 
resistance. Conditioned medium from IMR-90 fibroblasts in the lower chamber was used to attract 
tumor cells (4x104 ) seeded atop the endothelial layer during a 16 hr migration period. Where indicated, 
washed human platelets (433x103/l) were added to the tumor cell suspension, with or without 
stimulation with thrombin receptor activating peptide TRAP-6 (12.5 M). Non-migrated tumor cells 
were removed from the filter tops with cotton swaps, filters fixed in 4% paraformaldehyde and 
transmigrated tumor cells counted by fluorescence microscopy on the filter underside in 5 optical fields.  
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Results 
 
Tumor cell model for investigating a role of integrin v3 activation in hematogenous metastasis 
 
To identify critical steps within the metastatic cascade affected by the activation state of integrin v3 
and to analyze mechanisms involved, we generated a model of tumor cell of variants with a common 
genetic background and defined levels of v3 expression and activation. We chose MDA-MB 435 
human tumor cells because of their aggressive metastatic behavior in immune deficient mice, which 
makes them suitable for following individual steps of the metastatic cascade (23). The majority of 
MDA-MB 435 parental cells expresses integrin v3, but this population is heterogeneous and contains 
a subset that expresses v3 in a constitutively activated functional form, while most cells express the 
non-activated integrin (13). Our previous results indicate that cells carrying activated v3 are selected 
as the metastasis forming cells when the parental cells are injected into the blood stream (13). To 
generate cells with defined states of v3 activation without in vivo selection, which may favor 
additional properties unrelated to v3, we cloned MDA-MB 435 cells by limiting dilution and 
analyzed 25 individual clones for v3 expression and activation state. Clone E9 was identified as 
carrying v3 in a constitutively activated form because it bound soluble v3 ligands including the 
v3 specific ligand-mimetic scFv antibody Bc-15. We previously isolated this antibody from a 
combinatorial immunoglobulin library and showed that it contains an RGD integrin-binding motif 
typical for v3 ligands within CDR-H3 (20). Twenty cell clones, each of which expressed v3 but 
failed to bind Bc-15 and other soluble v3 ligands were pooled and named Parent Combo. These cells 
uniformly express non-activated v3. Figure 1 summarizes v3 expression and activation in the used 
cell variants. Bc-15 binding in the presence of calcium indicates that v3 is activated.  Binding in the 
presence of manganese indicates that intrinsically non-activated v3 can be experimentally activated to 
recognize soluble ligand. Manganese also maximizes intrinsic v3 activation. Based on these criteria, 
the cells carrying intrinsically activated v3 are clone E9, BCM2, and 3D723R mutant expressing 
cells. BCM2 were isolated after exposing very low numbers of MDA-MB 435 parental cells to human 
blood and recovering surviving, proliferating tumor cells. 3D723R cells were generated by 
reconstituting a 3-lacking subpopulation of MDA-MB 435 (3minus) with the activating 3 mutant gene. 
Reconstitution with the 3 wild type gene (3WT) results in non-activated v3 expression {7809}.  
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Functional validation of tumor cell integrin v3 activation 
 
Before investigating steps within the metastatic cascade where the activated form of tumor cell integrin 
v3 may exert its pro-metastatic properties, we verified the functional activation state of the receptor in 
our cell model. Cells carrying the activating mutant 3D723R were compared against 3minus cells,  
activated clone E9, and non-activated pool Parent Combo. We analyzed two metastasis related tumor 
cell functions that are mediated by integrin v3 and which require the activated, high affinity state of 
the receptor (15, 24).  One functions is migration toward a fibrinogen substrate, which is exclusively 
supported by v3 on these cells (21). The other function is tumor cell attachment to components of the 
vessel wall during blood flow. This process depends on activated v3 to bind soluble plasma proteins, 
such as fibrinogen, and cross link the tumor cells with platelets which then supports the arrest event 
(14). We found that the 3D723R expressing cells as well as clone E9, but not the 3minus and Parent 
Combo cells, migrated actively toward fibrinogen and this was blocked by an inhibitory anti-3 
antibody (Fig.2A). Consistent with this finding, 3D723R expressing cells and clone E9, but not 3minus 
and Parent Combo cells were able to arrest on a collagen I matrix during blood flow in a platelet-
dependent manner. The interaction of 3D723R cells and clone E9 with platelets during blood flow and 
the ability of the tumor cells to arrest were inhibited by a function blocking anti-v3 antibody 
(Fig.2B). Cells expressing 3WT that failed to bind soluble ligand binding as seen in Fig.1 also failed to 
interact with platelets and arrest during blood flow, confirming that v3 is not activated (Fig.2B). 
Thus, our cell model contains variants in which the adhesion receptor integrin v3 is expressed either 
constitutively activated (3D723R cells and clone E9) or not activated (Parent Combo and 3WT cells). 
BCM2 cells behaved like 3D723R cells and clone E9, confirming v3 activation (not shown). 
 
 
Activation of tumor cell integrin v3 promotes initial steps of target organ colonization from the 
blood stream but does not affect primary tumor growth 
 
To identify steps within the metastatic cascade in which the activation state of tumor cell integrin v3 
limits success, we first examined the ability of the cells to form a primary tumor. This was done in chick 
embryos and in the mammary fat pad of SCID mice. The chick model was chosen because it also allows 
analysis of tumor cell dissociation from a primary tumor and intravasation (18). After inoculating tumor 
cells (2x106) expressing activated mutant receptor v3D723R versus cells expressing non-activated 
 8
v3WT onto the chorioallantoic membrane (CAM) near the allantoic vein of 10 day old chick 
embryos, tumors were induced by each cell line and grew at similar rates. They also showed similar 
rates of intravasation, measured by the number of tumor cells in the lower CAM seven days after 
implantation (578346 3D723R, 641225 3WT, n=7/group). Quantification was based on real time 
PCR of the human alu sequences as described (18). Similarly, 3D723R expressing cells and those 
carrying 3WT, as well as 3minus cells grew at comparable rates when injected into the mammary fat 
pad of SCID mice (Fig.3A). Thus, the expression of v3 and its functional activation state apparently 
do not limit tumor formation at a primary site or the ability of tumor cells to gain access to the 
circulation.  
 
We next examined tumor cell colonization of target organs from the blood stream. At this step, 
expression of constitutively activated v3 provided the tumor cells with a clear advantage. Following 
tumor cell arrest and expansion in the lungs of SCID mice after tail vein injection by fluorescence 
microscopy and alu PCR indicated that cells expressing activated v3D723R remained in the 
pulmonary vascular bed and developed metastatic foci more successfully than cells carrying non-
activated v3WT. Of 1x106 injected cells, 8.5-9.5x105 were found in the lungs 3 hours later regardless 
of v3 activation. For both cell types, this number dropped sharply within the next 12 hours and 
reached a low point at 24 hours. At this time and during the following 18 days, 3WTexpressing cells 
were barely detectable in the lungs while 3D723R carrying cells maintained a level of about 1x105 
cells at 24 hours and then increased steadily, exceeding 2.5x108 cells compared to only 8x105 3WT 
cells on day 35 (Fig.3B). Clearance of tumor cells from lung tissue within the first 24 hours and the 
early advantage of the 3D723R expressing cells were confirmed by fluorescence microscopy 
monitoring dsRed tagged cells within the lungs (Fig.3C). Intravital microscopy of lung tissue grafts, 
grown within dorsal skin fold chambers on SCID mice, allowed to detect the arrest process of 3D723R 
expressing cells within the pulmonary microvasculature  (Fig. 3D). While the arrest events were rare and 
not suitable for quantification as only small tissue areas could be observed over time, the captured 
images provide evidence that activated v3 expressing cells can successfully arrest within the 
pulmonary vascular bed. No arrest events were observed after injection of non-activated 3WT 
expressing cells. Together, these results indicate that activated integrin v3 endows circulating tumor 
cells with functional properties that enhance the ability of the cells to colonize the lungs from the blood 
stream. An initial advantage of tumor cells carrying high affinity v3 translates into enhanced 
metastatic burden over time.  
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Integrin v3 activation promotes hematogenous metastasis to multiple sites 
 
We next asked if the advantage conferred to the tumor cells by the high affinity receptor is specific for 
colonizing the lung, or if v3 activation more generally promotes metastasis from the blood stream. To 
address this question, we used variants of our cell model that carry intrinsically activated v3. It is not 
known whether tumor cell subpopulations that express the activated integrin in vivo permanently carry 
the receptor in a high affinity form, or if the activation state is dynamically regulated. Therefore and 
because of other potential genotypic and phenotypic alterations that might be associated with intrinsic 
activation of integrin v3, we compared the metastatic activity of tumor cells with intrinsically 
activated versus non-activated v3 and monitored the distribution of metastatic lesions by non-
invasive bioluminescence imaging of SCID mice injected with firefly luciferase (F-luc) tagged tumor 
cells.  
 
E9 cells, cloned in vitro from the parent, express intrinsically activated v3 (Fig. 1). When injected 
into the venous circulation, E9 cells actively produced metastatic lesions in the lungs and other target 
organs of breast cancer and melanoma metastasis. In contrast, Parent Combo cells, representing a pool 
of 20 clones with non-activated v3, poorly colonized the lungs and other sites. Figure 4A shows 
typical organ distribution and quantification of metastatic burden in the lungs comparing clone E9 and 
Parent Combo cells. The differences in lung colonization were statistically significant when measured 
14 days after tail vein injection of 1x105 tumor cells, as well as 34 days after injecting 1x106 tumor cells, 
to challenge the system. Ex vivo imaging of excised target organs on day 56 revealed increased 
incidence of metastasis to multiple sites for clone E9 expressing the activated integrin (Fig. 4B). This 
enhancement of overall metastatic activity and potential to colonize most major target organs of breast 
cancer and melanoma metastasis from the blood stream, was confirmed with BCM-2 cells, a polyclonal 
derivative of MDA-MB 435 cells that also expresses intrinsically activated v3 (Fig. 1). Tail vein 
injected BCM-2 cells colonized the lungs, brain, liver, adrenal glands and skeletal bone, as seen by non-
invasive bioluminescence imaging and histology (Fig. 4B). Similar results were obtained with 3D723R 
cells carrying the experimentally activated mutant receptor.  These results indicate that expression of 
high affinity integrin v3 provides blood borne tumor cells with a critical advantage during the 
colonization of major target organs of metastasis.  
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Activated tumor cell integrin v3 cooperates with platelets to promote metastasis from the blood 
stream 
 
To analyze mechanisms by which the expression of tumor cell integrin v3 in a high affinity state 
supports early steps of metastasis from the blood stream, we followed a key function of the activated 
integrin that initially lead us to appreciate distinct affinity states of v in tumor cells, namely the 
ability of the activated receptor to promote tumor cell interaction with platelets (13, 14).  Here, we asked 
if an interaction between tumor cells and platelets could promote not only initial tumor cell arrest within 
the target organ microvasculature but also subsequent steps of organ colonization. After attaching to the 
microvascular endothelium of target organs, metastatic tumor cells penetrate the endothelial barrier 
before invading target tissues. To investigate this step, we analyzed the effect of v3 activation on 
tumor cell transendothelial migration in the presence or absence of platelets. Comparing cells expressing 
experimentally (3D723R) or intrinsically (BCM2) activated v3 against cells carrying the non-
activated integrin (3WT) revealed that either cell type poorly penetrated monolayers of human 
pulmonary microvascular endothelial cells in the absence of platelets. However, when platelets were 
present, tumor cells with activated v3 transmigrated very efficiently in contrast to cells with the non-
activated integrin. This response was enhanced when platelets were stimulated with thrombin receptor 
activating peptide (TRAP-6) (Fig.5A). Platelet failed to support tumor cell-transendothelial migration if 
they had previously released their -granule contents and were washed before addition to tumor cells 
and endothelial monolayers (Fig.5A). Platelet releasate alone potentiated tumor cell-induced endothelial 
retraction in 2D cocultures (not shown). This indicates that tumor cell interaction with platelets, and 
platelet activation resulting in the release of proteins and stimulants contained in platelet granules, 
strongly promote tumor cell penetration of the lung microvascular endothelium. Importantly, this 
cooperation with platelets depended on the activated state of tumor cell integrin v3, as cells 
expressing the non-activated wild type receptor (Fig.5A) and 3 knock-down cells (not shown) largely 
failed to penetrate the endothelium regardless of the presence of platelets. TRAP-6, used for platelet 
stimulation, alone had no effect on tumor cell transendothelial migration (Fig.5A). 
 
To examine if the in vitro observed effect of platelets on tumor cell invasion of the lung microvascular 
endothelium is relevant for hematogenous metastasis in vivo, we rendered SCID mice thrombocytopenic 
and followed the fate of injected tumor cells within a time window of reduced platelet counts. 
Thrombocytopenia was induced by injecting mice with an antibody against murine platelet receptor 
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GPIb. This treatment reduced platelet counts 10-fold from an average of 823x103/l to 72x103/l four 
hours after antibody injection. Counts remained low for 4 days before returning to normal. To examine 
if platelets support early events of target organ colonization, 5x105 tumor cells with activated v3, 
namely 3D723R cells and BCM2, were injected into the venous circulation 4 hours after treatment with 
anti-platelet antibody when platelet counts reached the low point. Three days later, within the time of 
reduced platelet counts, the lungs were examined by histology in serial sections throughout the lung 
tissue. As shown in Table 1, the number of detectable micrometastases for both tumor cell types was 
reduced in thrombocytopenic mice. Importantly, it was possible to discern extravasated from 
intravascular tumor cell nests by analyzing the integrity of basement membranes and the endothelium of 
the pulmonary microvasculature. Tumor cells clearly surrounded by intact endothelium were classified 
as intravascular. Tumor cells detected in thrombocytopenic animals largely failed to extravasate, while 
almost all tumor cells in mice with normal platelet counts were found outside the vasculature (Fig.5B). 
Furthermore, the majority of tumor cells in mice with normal platelet counts began to proliferate and 
incorporate BrdU on day 3 post injection, while the percentage of BrdU-positive tumor cells was 3.6-3.9 
fold reduced in thrombocytopenic animals (Tab.1). Inhibition of tumor cell extravasation by reducing 
platelet counts early during target organ colonization from the blood stream translated into reduced 
numbers and sizes of metastatic foci in the lungs 18 days after tumor cell injection (Fig.5C). Considering 
that platelet counts remained low only during the first 4 days after tumor cell injection, and then returned 
to normal allowing micrometastases to develop in the presence of normal platelet counts for the 
following 14 days, the overall reduction in metastatic burden indicates that platelets indeed played a 
major role during the initial steps of target organ colonization from the blood stream. Thus, an absence 
of platelets or the inability of tumor cells to cooperate with them can limit metastatic activity. The 
finding that activation of tumor cell integrin v3 promotes cooperation with platelets in support tumor 
cell extravasation as a critical early step of target organ colonization from the blood stream provides a 
mechanism through which the high affinity form of the integrin promotes metastasis.  
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Discussion   
 
The metastatic cascade comprises discrete steps in each of which tumor cell musts succeed to establish 
distant lesions (25). Knowledge about mechanisms supporting individual steps of the dissemination 
process can help define molecular and functional targets for therapeutic intervention and possibly 
prevention of metastatic disease.  
 
This study has yielded insight into the role of integrin activation in human tumor metastasis and 
identified extravasation of circulating tumor cells as a step where the affinity state of tumor cell integrin 
v3 makes a critical contribution. 
 
The adhesion receptor integrin v3 allows tumor cells to attach and migrate on extracellular matrix 
proteins including vitronectin, fibronectin, fibrin, and von Willebrand Factor (26). Ligation of the tumor 
cell receptor can transduce signals that promote survival, proliferation, and expression of genes 
supporting invasion, growth factor responses and stromal interaction (6, 27). In tumors such as 
melanoma, glioma, breast and ovarian cancer, v3 appears in invasive margins and distant lesions, and 
is associated with malignant progression (26, 28-31). Analyzing metastasis promoting tumor cell 
functions, we noted earlier that tumor cells can express integrin v3 in distinct states of activation and 
that cells from metastatic lesions carry the integrin in a constitutively high affinity form (13). 
Importantly, targeting of the activated conformer of v3 on circulating tumor cells with RGD 
containing ligand mimetic antibodies from cancer patients prevented metastasis from the blood stream 
(20).  
 
As most prominently shown for platelets and leukocytes, changes in integrin affinity allow the cells to 
control their adhesive properties within the blood stream and during transit between the circulation and 
tissues. Prototypic receptors capable of rapid activational changes are platelet integrin IIb3 and 
leukocyte integrins M2, L2, and 41 (4, 8). Furthermore, activation of several other 1 integrins 
was noted in different cell types associated with their relocation between tissue niches during 
development, tissue remodeling, and wound healing (7, 32-34).  While external signals, agonist 
stimulation and binding to multivalent ligands can trigger integrin activation from the outside-in (3), 
constitutive activation as noted for tumor cell v3 in our previous studies likely depends primarily on 
inside-out signals that lead to constraints in the molecular structure of the   heterodimer (2). 
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Crystallographic analyses of v3 (35, 36) showed that large-scale reorientations of the subunit 
ectodomains are linked to conformational changes in transmembrane domains (4). This involves 
formation of integrin activation complexes with intracellular integrin binding proteins, such as talin and 
Rap1-GTP-interacting adaptor molecule RIAM, which results in enhanced receptor affinity without 
altering receptor valency (8, 37). Recent evidence further suggests that oxidation of redox sensitive 
cystein residues in integrins can also trigger conformational changes leading to integrin activation and 
receptor redox modulation (38). This mechanism could be highly relevant in the dynamic control of 
integrin affinity within microenvironments of activated leukocytes and, perhaps, metastasizing tumor 
cells that can alter their metabolic properties and production of reactive oxygen species in response to 
new tissue environments. Our recent proteomic study of bone and brain metastatic cells indicated organ 
specific metabolic adaptation of the tumor cells with prominent changes in oxidative pathways and 
redox potential of the cells (17).  
 
To identify steps within the metastatic cascade that are specifically supported by tumor cell integrin 
v3, among the many other integrins and adhesion receptors expressed by disseminating tumor cells, 
and to pin-point in which mechanisms the activation state of v3 limits the rate of metastatic progress, 
we chose a cell model where v3 was identified as important for metastasis and in which proof-of-
principle exists for the requirement of v3 activation for the metastatic phenotype (13). We used the 
MDA-MB 435 cell system because it exemplifies a heterogeneous tumor cell population in which the 
majority of the cells express non-activated v3, while a small subset carries the high-affinity receptor 
apparently in a constitutively activated format. Our previous results indicate that this subset is likely 
responsible for metastasis (13). However, in vivo mechanisms providing these cells with a critical 
advantage during dissemination were unknown. Here we used variants of the MDA-MB 435 model, 
which share a genetic background and in which the v3 activation state was either controlled 
experimentally be introducing a 3 mutation that renders the heterodimer consitutively active 
(3D723R) (39), or which were selected in vitro from the parental cell population and validated for a 
stable functional activation state of the receptor. In each of these variants, the general integrin 
expression profile, including that of other v integrins were unaltered. Thus, this model allowed us to 
follow the specific contribution of activated v3 to distinct steps of the metastatic cascade, and to 
identify tumor cell extravasation from the blood stream as a rate-limiting step which requires the high 
affinity receptor. We found, in vitro and in vivo, that successful transendothelial migration further 
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depended on a cooperation between the tumor cells and platelets and involved the release of platelet 
granules.  
 
Platelet  granules contain a multitude of adhesive ligands, coagulation proteins, pro and anti-
angiogenic factors, growth factors, chemokines, cytokines, proteases and bioactive lipid metabolites, 
many of which directly affect endothelial cells and the integrity of the vascular endothelium.  For 
example, platelet released sphingosine 1-phosphate induces rapid loss of endothelial tight junction 
proteins ZO-1 and Claudin-18 (40), and lysophosphatidic acid induces vascular permeability (41). 
Metalloproteinases, and other proteases from platelet  granules, may facilitate extravastation of 
leukocytes and monocytes, specifically when activated by thrombin within the platelet 
microenvironment (42, 43). Furthermore, junctional adhesion molecules, such as JAM-C and adhesion 
receptor GPIb expressed on platelets, can serve as binding partners for leukocyte integrin M2 and 
support monocyte and neutrophil extravasation, as well as recruitment of cytotoxic T cells (44-48). Such 
mechanisms might also be involved in the ability of platelets to support angiogenesis (49, 50).  
 
Our results show that platelets and their released factors can very potently promote tumor cell 
transendothelial migration, and that platelets are in fact required for extravasation of circulating tumor 
cells in vivo. This platelet-mediated effect, supporting an initial critical step of target organ colonization 
by circulating tumor cells, depends on the expression of the activated form of tumor cell integrin v3 
in our model. It is possible that platelets, activated within the local microenvironment of tumor cells that 
have arrested within the capillary bed of target organs, promote endothelial permeability and allow 
tumor cells expressing the activated form of integrin v3 to efficiently use the receptor for penetration 
of the vessel wall and infiltration of target tissues. This potential mechanism is supported by our 
previous finding that functional activation of v3 enhances tumor cell migration and promotes 
activation of metalloproteinases, such as MMP-9 (21). In addition, our in vitro perfusion studies 
indicated that platelets may also critically contribute to tumor cell arrest during blood flow through an 
interaction mediated by activated tumor cell integrin v3. In its high affinity form, v3 is capable of 
binding soluble ligands, such as fibrinogen, that can crosslink tumor cells to platelet integrin IIb3 (13, 
14). This interaction, resulting in platelet supported tumor cell arrest in the microvasculature, resembles 
platelet-platelet cohesion during thrombus formation and platelet-leukocyte interaction via platelet 
receptors and activated leukocyte integrin M2 in inflammation. It is conceivable that platelet 
supported tumor cell arrest could promote tumor cell interaction with the endothelium in a variety of 
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capillary beds, potentially with or without help from potential target organ specific endothelial receptors, 
and assist tumor cells in colonizing multiple tissues in which the tumor cells can thrive. Indeed, our data 
indicate that tumor cells expressing the activated form of integrin v3 and therefore capable of 
interacting with platelets, show enhanced metastatic activity in all major target organs examined, and 
that reduction in platelet numbers lead to a general decrease in metastatic activity from the blood stream. 
This involves specific adhesive interactions and is not due to unpecific blockage of microvessels by 
platelet-tumor cell heteroaggregates, because we found no evidence for tumor cell induced thrombus 
formation in platelet aggregation studies, or thromboembolism by intravital microscopy and histology.  
 
Considering that experimentally induced thrombocytopenia during the initial four days after tumor cell 
injection strongly inhibited tumor cell extravasation in the mouse model, and with it significantly 
reduced metastatic burden in the long run, indicates that platelets play a critical role in early steps of the 
metastatic cascade when tumor cell disseminate via the blood stream. The cooperation between tumor 
cells and platelets gives tumor cells carrying the activated form of integrin v3 direct, and possibly 
indirect advantages for target organ colonization. Together, this study identifies the activated form of 
tumor cell integrin v3 as critical for early steps of metastasis from the blood stream and highlights the 
high affinity conformation of the receptor as a potential therapeutic target for prevention of metastatic 
disease. 
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Figure Legends 
 
Figure 1. 
Tumor cell model for integrin v3 activation in tumor metastasis 
Flow cytometry analysis of tumor cell variants expressing defined levels and activation states of integrin 
v3. The cell variants were selected from MDA-MB parental cells in vitro or generated by 
experimental expression of 3 subunit gene variants. Left panels: integrin v3 heterodimer expression 
(Mab VNR1). Right panels: integrin v3 activation state measured by binding of soluble ligand 
mimetic scFv antibody Bc-15. This human scFv antibody carries an RGD sequence within CDR-H3 and 
behaves like a natural ligand of the receptor but has the specificity of an antibody and recognizes v3 
only. Lack of scFv binding in the absence of divalent cations (blue lines = no cations) indicates cation 
dependence. Intrinsic activation of integrin v3 allows scFv binding in the presence of calcium  
(1mM) (red line = Ca), while low or no binding in calcium indicates non-activated v3 in cells that 
express the receptor. ScFv binding in the presence manganese (50 M) (green line = Mn) is maximized, 
regardless of the intrinsic v3 activation state, as long as the cells are v3 positive. Bold red +/- signs 
on the right indicate the v3 activation state. 
BCM2 cells were isolated by exposing low cell numbers of the parental cell population to human blood 
and selecting surviving, proliferating tumor cells. These cells express intrinsically activated v3. 
Parent Combo cells (PaCo) were selected from the parental cell population by single cell cloning and 
combining 20 clones each of which express non-activated v3 based on a panel of functional assays, 
including haptotactic cell migration and blood perfusion as detailed in Figure 2. E9 cells represent a 
single clone isolated by limiting dilution, expressing intrinsically activate v3. 3 minus cells largely 
lack v3 expression and were selected by exposing the parental cell population to anti-3 antibody 
coupled to saporin to kill 3- positive cells. 3WT cells are 3minus cells transfected with the 3 wild 
type subunit gene resulting in the expression of non-activated v3. 3D723R cells are 3minus cells 
transfected with the 3 D723R mutant subunit gene, resulting in the expression of intrinsically activated 
v3.  
 
Figure 2. 
Functional validation of tumor cell integrin v3 activation  
A, Haptotactic migration toward immobilized fibrinogen requires expression of integrin v3 in an 
activated functional state. MDA-MB 435 cells selected for lack of 3 expression (3 minus) failed to 
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migrate in contrast to their counterparts reconstituted with the constitutively activating 3mutant D723R 
(p<0.002). Migration of 3 mutant D723R expressing cells is strongly inhibited by blocking anti-3 
antibody (mab M21-3 at 50 g/ml) (p<0.002). E9 cells, a single clone isolated from parental MDA-MB 
435 cells by limiting dilution, express the same amount of v3 as Parent Combo cells, a pool of 20 
clones expressing the non-activated integrin, but in contrast to Parent Combo cells, E9 cells express 
v3 in an intrinsically activated form and migrated actively toward fibrinogen (p<0.001) (16 hr 
migration at 37C toward human fibrinogen immobilized at the underside of transwell insert filters with 8 
m pores). 
B, Left Panel: The ability of tumor cells to attach during blood flow to matrix components of the vessel 
wall depends upon and indicates the activated state of tumor cell integrin v3. MDA-MB 435 3 
minus, 3D723R, E9, and Parent Combo cells were suspended in whole human blood and perfused over 
a collagen I matrix at a venous wall shear rate of 2 dynes/cm2 in a parallel plate flow chamber. Tumor 
cells expressing activated v3 use the receptor to interact with platelets and, as a result, arrest at the 
matrix in the presence of shear generated by blood flow. Middle Panel: In 3D723R expressing cells 
and clone E9, the ability to arrest during blood flow is mediated by v3, as this function is blocked by 
anti v3 antibody (mab VNR1-27.1 at 50 g/ml). Right Panel: Typical images, captured at predefined 
positions, during flow of blood containing either MDA-MB 435 3D723R (left) or 3WT (right) 
expressing cells. The top images, acquired with filter settings for green fluorescence (top images) show 
arrested blood cells and thrombus forming platelets. The bottom images were captured at the same 
positions as their corresponding top images but with filters detecting red fluorescence identify the 
arrested tumor cells. Arrested tumor cells were quantified at 50 predefined positions during ongoing 
perfusion after same number of tumor cells for each cell type were allowed to pass through the chamber. 
Statistical significance was assessed by paired, one-tailed t-tests. 
 
Figure 3. 
Activation of tumor cell integrin v3 promotes initial steps of target organ colonization from the 
blood stream but is not required for primary tumor growth  
A, Tumor cell growth within the mammary fat pad as a primary site does not depend on integrin v3 
expression or the activation state of the receptor. MDA-MB 435 cells selected for lack of 3 expression 
(3-), reconstituted with 3 wild type (3WT), or with the constitutively activating mutant 3 
(3D723R) grew at similar rates after injecting 1x106 cells into the mammary fat pad of SCID mice 
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(n=8). Tumor sizes were measured with calipers by the longest and shortest diameter and calculating the 
volume as (a2xb)/2. 
B, Quantification of tumor cells in SCID mouse lungs at varying time points after tail vein injection of 
1x106 dsRed tagged MDA-MB 435 cells expressing either constitutively activated v3D723R or non-
activated v3WT. Tumor cells were quantified at the indicted time points by real time PCR of human 
alu sequences within the lung tissue. The initial signal at 3h post injection was nearly identical for both 
cell types and reflects tumor cells within the pulmonary microcirculation, most of which are cleared 
during the first day. Bars indicate numbers of lung associated tumor cells (n=5 mice), shown as percent  
( SEM) of the initial tumor cell number at 3 h post injection. Cell numbers are based on PCR standard 
curves, obtained from lung homogenates spiked with known tumor cell numbers. 
C, Lung whole mounts 3 to 12 hrs after tail vein injection of dsRed tagged tumor cells as in B, 
visualizing the tumor cells by fluorescence microscopy (10x). Representative fields are shown. 
D, Arrest of 3D723R expressing cells within the pulmonary microvasculature observed by intravital 
microscopy. Lung allografts were grown in dorsal skin fold chambers on SCID mice, allowed to 
vascularize for 14 days before superfusion with TNF (50l at 1g/ml) 2.5 hours prior to i.v. injection 
of 2.5x106 dsRed tagged tumor cells together with FITC-dextran (500 kDa) to visualize the vasculature. 
Circulation and adhesive events were recorded by intravital video microscopy (Leitz Biomed). Bar, 50 
m. 
 
Figure 4. 
Integrin v3 activation promotes hematogenous metastasis to multiple target organs  
A. Left panels: Metastatic activity of MDA-MB 435 clone E9 expressing intrinsically activated integrin 
v3 compared to 20-clone pool Parent Combo expressing non-activated v3. Non-invasive 
bioluminescence imaging of SCID mice 14 days after tail vein injection of 1x105 F-luc tagged tumor 
cells. Right panels: Quantification of metastatic burden in the lung region by non-invasive 
bioluminescence imaging 14 days after injecting 1x105 tumor cells (Top), or by real time PCR 34 days 
after injecting 1x106 tumor cells to challenge the system and following the tumor cells by human alu 
sequences (Bottom ). Each data point in the top panel represents signal from one mouse (n=8), the 
vertical line indicates the median signal in each group. Bars in the lower panel show average values (+/- 
STDEV) for each group (n=8).  Clone E9 caused significantly higher metastatic lung burden than clone 
pool Parent Combo (p=0.002 by bioluminescence imaging on day 14 after 1x105 injected tumor cells ; 
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p= 0.05 by alu PCR 34 days after 1x106 injected tumor cells). Statistical significance was assessed by 
paired, one-tailed t-tests. 
 
B. Comparison of target organ colonization by tumor cells expressing activated versus non-activated 
v3. Incidence of tumor cell burden in the lungs, brain, liver, adrenal glands and bone (hind legs) 56 
days after tail vein injection of 1x105 clone E9 versus clone pool Parent Combo. Organ associated 
metastatic burden was detected in excised organs by ex vivo bioluminescence imaging, n= 8 mice per 
group. The presence of metastatic lesions was verified by histology (right panels). Brain lesion H&E 
staining, Bar 80m. Liver lesion, top panel identifies tumor lesions by immunohistochemistry with anti 
human CD44 (Mab 29.7) (dark blue), bottom panel shows a neighboring section stained with H&E and 
lesions marked with blue asterisks, Bar 200 m. Adrenal gland section shown by H&E staining, lesions 
marked with blue asterisks, Bar 150 m. Mouse images: Multiple target organ colonization validated 
with polyclonal cell population BCM2 which express activated integrin v3. Non-invasive 
bioluminescence imaging of metastasis development in distinct target organs 56 days after tail vein 
injection 2.5x105 tumor cells. Three representative mice are shown (ventral and dorsal). Metastatic 
burden in the lungs, liver, brain, spine, and adrenal gland was confirmed by bioluminescence imaging of 
the excised organs and by histology as above.  
 
Figure 5.  
Activated integrin v3 promotes tumor cell cooperation with platelets in support of extavasation 
and metastasis from the blood stream 
A. Platelets and activated tumor cell integrin v3 together promote tumor cell transendothelial 
migration in vitro. In the presence of platelets, MDA-MB 435 cell variants with activated mutant 
v3D723R, or expressing intrinsically activated v3 (BCM2), penetrated monolayers of human lung 
microvascular endothelial cells more efficiently than tumor cells with non-activated v3WT (p=0.03). 
Experimental platelet activation with TRAP-6 (thrombin receptor activating peptide-6, a PAR1 agonist) 
before addition to the tumor cells, slightly enhances the stimulatory effect of platelets on tumor cell 
transendothelial migration (p=0.13 for D723R, p=0.21 for BCM2). TRAP-6 alone, or exhausted 
platelets stimulated with TRAP-6, allowed to release their  granules and washed before addition to 
tumor cells, did not enhance tumor cell transendothelial migration.  
B. Experimental thrombocytopenia prevents tumor cell extravasation in vivo and inhibits metastasis. 
SCID mice were injected with a polyclonal antibody against mouse platelet glycoporotein GPIb (3g/g 
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bodyweight) to induce temporary thrombocytopenia. After 4 hrs, platelet count were reduced from an 
average of 823x103/l to an average of 72x103/l and remained low for 4 days before returning to 
normal. 4 hours after induction of thrombocytopenia, 5x105 3D723R expressing cells or BCM2, both 
expressing activated integrin v3, were injected into the tail vein. Representative microscopic images 
of lung sections show tumor cells 3 days after injection into mice with normal platelet counts (top) or 
10-fold reduced platelet counts (bottom). With normal platelet counts, multiple tumor cell clusters 
(green arrows) are seen within the lung tissue outside of blood vessels. With reduced platelet counts, few 
small tumor cell clusters are seen and almost always found inside blood vessels (green arrow). Bars 100 
m. Quantification of in vivo tumor cell extravasation on Day 3 is summarized in Table 1. 
C. Experimental thrombocytopenia reduces metastasis from the blood stream. SCID mice were injected 
with anti platelet glycoprotein GPIb as above or PBS for control (n=6). Four hours later the platelet 
count had dropped from an average of 775x103/l to an average of 65x103/l in the antibody treated 
mice. At this time point, 1x105 sdRed tagged BCM2 tumor cells were injected into the tail vein and lung 
metastases counted microscopically in whole mounts of each lung lobe 18 days later. Bars denote the 
number of metastatic foci per lung  SEM, counted regardless of size. Images below show dsRed tumor 
cell lesions in lung whole mounts representative for each experimental group. Mice with normal platelet 
counts had significantly more metastases (p<0.05) than mice with thrombocytopenia. Generally, lesions 
in control mice were also considerably larger than lesions in anti-platelet treated mice. Differences in 
metastatic burden were confirmed by real time PCR of human alu sequences within the lung tissue (not 
shown). Statistical significance was assessed by paired, one-tailed t-tests. 
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Tumor cell 
type 
Platelet 
count 
Measured 
lung area 
(mm2) 
Number of 
metastases in 
measured area
Number of 
metastases / 
mm2 
 
% 
extravasated
% BrdU 
positive 
3D723R normal 85.3 
140.2 
35
83
0.410
0.592
100
95
68.6
62.4
3D723R reduced 109.6 
126.2 
9
22
0.082
0.174
0
0
15.5
18.6
BCM2 normal 84.4 
88.7 
52
38
0.616
0.428
92
100
67.2
63.0
BCM2 reduced 84.3 
86.7 
14
18
0.166
0.207
7
0
12.2
14.4
 
 
Table 1. Effect of platelets on tumor cell extravasation and early metastasis in vivo. 
Morphometric measurements of mouse lung sections 3 days after i.v. injection of MDA-MB 435 3D723R 
or BCM2 cells. Each cell type was injected into mice with normal or 10-fold reduced platelet counts 
(n=2/condition). Data for each mouse indicate the analyzed lung area, numbers of metastases found (lesion 
count regardless of size), number of metastases/area, percentage of lesions found intravascular (intact 
vascular endothelium/basement membrane), or near blood vessels with broken vascular basement membrane 
indicating extravasation. Also included is the percentage of lesions showing BrdU uptake (24 h in vivo pulse) 
indicating proliferative activity, regardless of lesion size. Tumor cell lesions in mice with normal platelet 
counts were generally considerably larger and had higher proliferative activity than lesions in 
thrombocytopenic mice.  
 
